Clinical trial
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the…
NCT00185835 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00185835 |
|---|---|
| Title | Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck |
| Official title | Phase I Study of Cisplatin And ZD1839 (IRESSA®) in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck |
| Lead sponsor | Stanford University, Other |
| Collaborators | American Society of Clinical Oncology AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Carcinoma, Squamous Cell |
| Intervention type | Drug |
| Interventions | ZD-1839, Cisplatin |
| Enrollment | 10 |
| Start date | Jun 1, 2002 |
| Primary completion | Jul 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: